Holen Sie sich die Stockscreener-App
18.07
1.43%
-0.13
Schlusskurs vom Vortag:
$18.20
Offen:
$18
24-Stunden-Volumen:
1.08M
Relative Volume:
0.59
Marktkapitalisierung:
$2.43B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-8.9015
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
-7.19%
1M Leistung:
-25.68%
6M Leistung:
-33.26%
1J Leistung:
-62.26%
1-Tages-Spanne:
$17.68
$18.72
1-Wochen-Bereich:
$17.68
$19.71
52-Wochen-Spanne:
$17.48
$50.98
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Vergleichen Sie APLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
18.06 | 2.43B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.43 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
598.50 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.19 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.99 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
RBC Capital Lowers Price Target on Apellis (APLS) Amid Market Survey Insights | APLS Stock News - GuruFocus
Craig Wheeler to Join Apellis Board of Directors - citybiz
Apellis Pharmaceuticals appoints new board member - Investing.com Australia
Apellis Announces Craig Wheeler To Join The Board Of Directors - marketscreener.com
Craig Wheeler joins Apellis board, brings biopharma expertise By Investing.com - Investing.com India
Apellis Pharmaceuticals appoints new board member By Investing.com - Investing.com India
Apellis Pharmaceuticals (APLS) Welcomes Craig Wheeler to Board of Directors | APLS Stock News - GuruFocus
Apellis Announces Craig Wheeler to Join the Board of Directors | APLS Stock News - GuruFocus
Apellis Announces Craig Wheeler to Join the Board of Directors - The Manila Times
RBC Cuts Price Target on Apellis Pharmaceuticals to $21 From $24, Keeps Sector Perform Rating - marketscreener.com
Former Momenta CEO Who Led $13.4B Johnson & Johnson Deal Takes Strategic Role at Apellis - Stock Titan
Apellis Pharmaceuticals (APLS) Target Price Reduced by BofA Ahead of Earnings | APLS Stock News - GuruFocus
BofA Adjusts Price Target on Apellis Pharmaceuticals to $41 From $44, Keeps Buy Rating - marketscreener.com
Geographic Atrophy Therapeutics Market Size in 7MM is expected - openPR.com
Fierce Biotech Layoff Tracker 2025: Mural lays off 90%; Pfizer sells site, cuts staff - Fierce Biotech
The Market Doesn't Like What It Sees From Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues Yet As Shares Tumble 26% - simplywall.st
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Apellis Pharma stock hits 52-week low at $21.66 amid market challenges - Investing.com Canada
Apellis Pharma stock hits 52-week low at $21.66 amid market challenges By Investing.com - Investing.com South Africa
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Raymond James Financial Inc. Purchases New Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS) - The Globe and Mail
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag - TradingView
Apellis Looks To Unlock Blockbuster Potential For Empaveli, SyfovreOn A Path To Profitability - RTTNews
Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals - Benzinga
Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation - TipRanks
Applis wins FDA review to expand Empaveli label (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases - MarketScreener
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN - The Manila Times
Breakthrough: EMPAVELI Scores Priority FDA Review After 68% Disease Reduction in Rare Kidney Disorders - Stock Titan
New complement C3 inhibitors disclosed in Apellis patent - BioWorld MedTech
(APLS) Investment Analysis - news.stocktradersdaily.com
Apellis Pharma stock hits 52-week low at $23.77 amid market challenges - Investing.com Australia
Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Apellis Pharma stock hits 52-week low at $23.77 amid market challenges By Investing.com - Investing.com South Africa
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Apellis Pharmaceuticals chief development officer sells shares worth $39,279 - MSN
Interesting APLS Put And Call Options For May 16th - Nasdaq
Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli - Yahoo Finance
Apellis Pharmaceuticals (APLS) Gets a Hold from Scotiabank - The Globe and Mail
Cardurion Taps Apellis Veteran Who Led 450% Team Growth for Top HR Role - StockTitan
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):